©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessMalignant hyperthermia, susceptibility; differential diagnosis


Short information

Comprehensive differential diagnostic panel for Malignant hyperthermia, susceptibility comprising 3 guideline curated and altogether 22 curated genes according to the clinical signs

Number of genes
5 Accredited laboratory test
Examined sequence length
25,2 kb (Core-/Core-canditate-Genes)
27,7 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications




Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity

Informations about the disease

Clinical Comment

As a "pharmacogenetic disorder" malignant hyperthermia is a severe reaction to certain anesthetics including anesthetic gases causing an increase in heart rate, hyperthermia, accelerated respiration, muscle rigidity, rhabdomyolysis and acidosis. Cardiac arrest and renal failure as well as disseminated intravascular coagulation can be acutely life-threatening. Affected individuals are also at some risk for "awake" malignant hyperthermia, in which the severe reaction occurs after physical activity, often while being sick. On the other hand, while malignant hyperthermia often occurs in people without other serious medical problems, Central Core and multiminicore disorders and STAC3 disorders are particularly associated with susceptibility to malignant hyperthermia. Susceptibility for maligne hyperthermia is often autosomal dominantly inherited, rarely autosomal recessively. The DNA diagnostic yield is at least 60%. Therefore, an inconspicuous molecular genetic result does not exclude the clinical diagnosis.

Reference: https://www.ncbi.nlm.nih.gov/books/NBK1146/


  • Alias: Hyperthermia of Anesthesia; Malignant Hyperpyrexia; Fulminating Hyperpyrexia 52
  • Allelic: Apnea, postanesthetic, susceptibility to, due to BCHE deficiency (BCHE)
  • Allelic: CPT II deficiency, lethal neonatal + infantile (CPT2)
  • Allelic: Central core disease (RYR1)
  • Allelic: Efavirenz central nervous system toxicity, susceptibility to (CYP2B6)
  • Allelic: Efavirenz, poor metabolism of (CYP2B6)
  • Allelic: Encephalopathy, acute, infection-induced, 4, susceptibility to (CPT2)
  • Allelic: Hypokalemic periodic paralysis, type 1 (CACNA1S)
  • Allelic: King-Denborough syndrome (RYR1)
  • Allelic: Minicore myopathy with external ophthalmoplegia (RYR1)
  • Allelic: Neuromuscular disease, congenital, with uniform type 1 fiber (RYR1)
  • Allelic: Thyrotoxic periodic paralysis, susceptibility to, 1 (CACNA1S)
  • [Medication-relevant polymorphisms in CYP2E1, CYP2B6, CYP2C9, CYP3A4, GSTP1, UGT1A9, SULT1A1, NQO1]
  • Acyl-CoA dehydrogenase, medium chain, deficiency of (ACADM)
  • Butyrylcholinesterase deficiency (BCHE)
  • CPT II deficiency, infantile (CPT2)
  • CPT II deficiency, lethal neonatal (CPT2)
  • CPT II deficiency, myopathic, stress-induced (CPT2)
  • Drug metabolism, altered, CYP2C8-related (CYP2C8)
  • Malignant hyperthermia susceptibility 1 (RYR1)
  • Malignant hyperthermia susceptibility 3 (CACNA2D1)
  • Malignant hyperthermia susceptibility 5 (CACNA1S)
  • McArdle disease (PYGM)
  • Metabolic encephalomyop. crises, recurrent, rhabdomyolysis, cardiac arrhyth., neurodegen. (TANGO2)
  • Myopathy due to myoadenylate deaminase deficiency (AMPD1)
  • Myopathy, congenital, Baily-Bloch (STAC3)
  • Rhabdomyolysis, cerivastatin-induced (CYP2C8)
  • Statin-induced rhabdomyolysis (CYP3A4)
  • Traboulsi syndrome: dislocated crystalline lenses, anterior segment abnorm, distinctive face (ASPH)
Heredity, heredity patterns etc.
  • AD
  • AR
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

No text defined